4,782 Shares in Guardant Health, Inc. $GH Purchased by Trivium Point Advisory LLC

Key Points

• Trivium Point Advisory LLC purchased 4,782 shares of Guardant Health, valued at approximately $249,000, during the second quarter, marking its entry into the company.
• Guardant Health reported a 31.0% year-over-year revenue growth in its latest earnings, with quarterly revenue of $232.09 million and an EPS of ($0.44), beating analyst estimates.
• Major institutional investors have significantly increased their holdings in Guardant Health, with 92.60% of the stock owned by institutional investors and hedge funds.

Trivium Point Advisory LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,782 shares of the company's stock, valued at approximately $249,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC grew its position in Guardant Health by 277.8% during the second quarter. Janney Montgomery Scott LLC now owns 20,574 shares of the company's stock worth $1,071,000 after buying an additional 15,128 shares in the last quarter. Signaturefd LLC grew its position in Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company's stock worth $33,000 after buying an additional 213 shares in the last quarter. MRA Advisory Group grew its position in Guardant Health by 7.1% during the second quarter. MRA Advisory Group now owns 16,353 shares of the company's stock worth $851,000 after buying an additional 1,078 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in Guardant Health during the first quarter worth about $12,634,000. Finally, Rhumbline Advisers lifted its stake in Guardant Health by 4.9% during the first quarter. Rhumbline Advisers now owns 175,432 shares of the company's stock worth $7,473,000 after purchasing an additional 8,202 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Trading Up 0.3%

NASDAQ:GH opened at $62.65 on Thursday. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $68.00. The firm has a 50 day moving average of $56.61 and a 200-day moving average of $49.25. The stock has a market capitalization of $7.81 billion, a P/E ratio of -18.70 and a beta of 1.53.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. During the same quarter last year, the firm posted ($0.84) EPS. The business's revenue was up 31.0% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. As a group, analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Activity at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of the business's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $54.16, for a total value of $117,256.40. Following the completion of the transaction, the director owned 851 shares in the company, valued at $46,090.16. The trade was a 71.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the transaction, the chief executive officer owned 2,123,499 shares of the company's stock, valued at $126,242,015.55. This trade represents a 12.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 302,691 shares of company stock valued at $17,981,965 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wolfe Research upgraded shares of Guardant Health from a "peer perform" rating to an "outperform" rating and set a $75.00 price target for the company in a research note on Thursday, September 25th. Wells Fargo & Company assumed coverage on shares of Guardant Health in a research note on Monday, September 22nd. They set an "overweight" rating and a $72.00 price target for the company. BTIG Research set a $80.00 price target on shares of Guardant Health in a research note on Thursday, September 25th. UBS Group raised their price target on shares of Guardant Health from $70.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, September 25th. Finally, Mizuho raised their price target on shares of Guardant Health from $65.00 to $70.00 and gave the stock an "outperform" rating in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating and twenty-two have assigned a Buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $65.25.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.